Connecting Biomedical Innovation With Global Opportunity
NGBiologics Institute is an independent nonprofit organization connecting promising biomedical technologies with investors, industry partners, institutions, and opportunities across international markets.
Biomedical innovation increasingly moves across borders. Technologies developed within one university, research institution, biotechnology company, or startup may have significant potential in markets far beyond the networks in which they originated.
NGB helps create those pathways.
Our platform brings together technology owners, biotechnology companies, research institutions, investors, healthcare organizations, commercial partners, and strategic stakeholders around biomedical technologies moving toward clinical, commercial, and broader market application.
Strong Science Deserves a Global Opportunity
Breakthrough technologies are developed every day across universities, research institutions, biotechnology companies, startups, and specialized laboratories.
Turning that innovation into real-world impact requires more than scientific progress.
It requires visibility.
It requires the right capital, licensing relationships, commercial partners, healthcare organizations, institutions, and market connections.
And increasingly, it requires the ability to identify opportunities beyond a technology’s country of origin.
NGB connects biomedical innovation with organizations and markets capable of helping it move forward.
We create visibility for promising technologies and help expand the network of organizations that can discover, evaluate, and engage with them.
Commercial Translation & Industry Partnerships
NGBiologics Institute, Inc. is a nonprofit scientific organization connecting promising biomedical technologies with scientific, institutional, and industry expertise to advance responsible development and public benefit.
American Institute of Advancement LLC, presented online as AIA Biomed, is a separate, privately owned for-profit company. Its commercial activities can include licensing, sourcing, distribution, and international market development under separately documented agreements. NGB’s scientific and institutional role is distinct from AIA’s commercial responsibilities.
AIA’s catalogues describe peptides and related compounds, cellular products, exosomes, and other extracellular vesicle platforms. Licensed healthcare professionals, researchers, and qualified organizations can contact AIA for product-specific information, documentation, and applicable access requirements.
The AIA link provides access to a separate commercial website. It does not constitute NGB certification of product approval, safety, effectiveness, or suitability for clinical use. Professional access alone does not authorize purchase or clinical use. Payments to AIA for goods or services are commercial payments, not charitable contributions to NGB.
What NGB Does
NGB creates pathways between biomedical innovation and global opportunity. NGB expands the visibility of biomedical innovation and creates connections across organizations, industries, and international markets.
Technology Visibility
We provide a dedicated platform where technology owners can present public information about biomedical technologies available for licensing, investment, strategic collaboration, commercialization, and international market development.
International Market Access
NGB helps identify markets where biomedical technologies may have additional clinical, institutional, strategic, or commercial potential. We connect technology owners with relevant organizations, decision-makers, and potential partners in those markets.
Strategic Connections
We bring together technology developers with investors, biotechnology companies, healthcare organizations, manufacturers, research institutions, distributors, and strategic partners.
Commercial & Institutional Pathways
NGB helps create connections that may lead to: Licensing · Investment · Distribution · Strategic Partnerships · Institutional Collaboration · Commercialization · Regional Market Development · Market Entry
Biomedical Innovation Has No Borders
A technology may originate in one country and find important applications in another.
Healthcare needs vary.
Institutional priorities vary.
Commercial environments vary.
Investment interest varies.
Market readiness varies.
These differences create opportunity.
NGB works across international relationships to identify where biomedical technologies may align with organizations, institutions, healthcare systems, investors, and commercial partners in other markets.
For technology owners, this can mean greater visibility beyond their existing geographic reach.
For investors and industry, it can mean earlier access to innovation originating outside their conventional sourcing networks.
For healthcare and institutional partners, it can create access to technologies and scientific capabilities being developed elsewhere in the world.Â
Â
NGB connects innovation with markets where it may have the opportunity to grow.
Areas of Focus
Regenerative Medicine
Technologies involving tissue repair, regeneration, engineered tissues, biomaterials, and related translational approaches.
Cell Therapy
Emerging cellular platforms and therapeutic technologies with applications across multiple areas of medicine.
Gene Therapy & Genome Engineering
Gene delivery, gene replacement, gene editing, genome engineering, and next-generation genetic medicine.
Diagnostics & Biomarkers
Advanced diagnostics, biomarkers, molecular technologies, and tools supporting earlier and more precise detection of disease.
For Scientists, Inventors & Technology Owners
Take Your Technology Beyond Its Existing Network
Scientific teams often build deep expertise around the development of a technology while commercial opportunities may exist far beyond the relationships surrounding the original research.
NGB creates an additional pathway to those opportunities.
Universities, biotechnology companies, research institutions, startups, inventors, and other technology owners can use the NGB platform to present technologies to organizations looking for biomedical innovation.
NGB also helps identify potential opportunities across selected international markets, where different healthcare needs, institutional priorities, investment environments, commercial structures, or strategic interests may create additional pathways for a technology.
Technologies may be:
- Available for licensing
- Seeking investment
- Seeking strategic or industry partners
- Preparing for commercialization
- Entering new markets
- In advanced or late-stage clinical development
- Ready for broader commercial application
- Seeking regional partners
- Exploring international market opportunities
Each technology profile gives potential partners a clear view of the opportunity and provides a starting point for further discussion.
Your technology may have a larger market than the one you currently see.
NGB helps expand that field of opportunity.
For Investors, Industry & Strategic Partners
Discover Innovation Beyond Your Existing Network
The next valuable biomedical opportunity may originate outside the institutions, companies, conferences, or geographic markets an organization already follows.
NGB provides a structured way to discover technologies across scientific disciplines, organizations, and international markets.
Investors, biotechnology companies, healthcare organizations, manufacturers, distributors, institutional partners, and strategic stakeholders can explore technologies seeking:
Investment
Biomedical innovations with potential for continued development and commercialization.
Licensing
Technologies available for licensing, regional rights, or commercial development.
Strategic Partnerships
Opportunities involving biotechnology companies, technology developers, manufacturers, healthcare organizations, research institutions, and other complementary partners.
International Market Development
Technologies whose scientific or commercial potential may extend into additional geographic markets.
Regional Commercialization
Opportunities for organizations with local market knowledge, healthcare relationships, infrastructure, distribution capability, or commercialization expertise.
Institutional Collaboration
Connections between scientific organizations, healthcare systems, research institutions, commercial partners, and other organizations with complementary capabilities.
NGB gives organizations another window into biomedical innovation—and a broader view of where opportunity may exist.
Beyond Technology Discovery
NGB Longevity Center
Building an Environment Around Healthy Longevity
NGB’s mission also extends to another important question:
How can knowledge about health and longevity be translated into the way people actually live?
NGB is developing a +100-acre property in Virginia as a longevity center focused on organic living, health, prevention, nature, and the practices associated with healthier and longer living.
The concept reflects a broad view of longevity.
Healthy longevity emerges through the interaction of multiple factors over time:
Nutrition · Physical Activity · Sleep · Environment · Prevention · Mental Well-Being · Social Connection · Purpose · Science · Healthcare
The Virginia center is intended to bring these elements together within one natural environment.